CN1455673A - 分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物 - Google Patents
分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物 Download PDFInfo
- Publication number
- CN1455673A CN1455673A CN02800047A CN02800047A CN1455673A CN 1455673 A CN1455673 A CN 1455673A CN 02800047 A CN02800047 A CN 02800047A CN 02800047 A CN02800047 A CN 02800047A CN 1455673 A CN1455673 A CN 1455673A
- Authority
- CN
- China
- Prior art keywords
- extract
- growth
- metabolite
- suppresses
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 41
- 239000003242 anti bacterial agent Substances 0.000 title description 2
- 229940088710 antibiotic agent Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 51
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 38
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 4
- 241000589774 Pseudomonas sp. Species 0.000 claims abstract description 3
- 241001147693 Staphylococcus sp. Species 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 52
- 230000012010 growth Effects 0.000 claims description 45
- 239000002207 metabolite Substances 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 22
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 14
- 241000233866 Fungi Species 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 5
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000000968 intestinal effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 21
- 230000000840 anti-viral effect Effects 0.000 abstract description 13
- 230000000843 anti-fungal effect Effects 0.000 abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 12
- 210000003097 mucus Anatomy 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 241000269333 Caudata Species 0.000 abstract description 3
- 241001480037 Microsporum Species 0.000 abstract description 3
- 244000052637 human pathogen Species 0.000 abstract description 3
- 241000269350 Anura Species 0.000 abstract description 2
- 241001495410 Enterococcus sp. Species 0.000 abstract description 2
- 241000488157 Escherichia sp. Species 0.000 abstract description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 description 32
- 241000269401 Plethodontidae Species 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 23
- 244000052616 bacterial pathogen Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 229920001817 Agar Polymers 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241000194032 Enterococcus faecalis Species 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940121375 antifungal agent Drugs 0.000 description 9
- 229940032049 enterococcus faecalis Drugs 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 8
- 230000012447 hatching Effects 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 6
- 241000269398 Plethodon Species 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 5
- 241000167565 Desmognathus Species 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 241000269799 Perca fluviatilis Species 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 241000508900 Desmognathus ochrophaeus Species 0.000 description 3
- 241000508899 Desmognathus quadramaculatus Species 0.000 description 3
- 241000167568 Eurycea Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000270974 Hylidae Species 0.000 description 3
- 241001249730 Plethodon cinereus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000186245 Corynebacterium xerosis Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000269436 Ranidae Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 244000062645 predators Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 241001316595 Acris Species 0.000 description 1
- 241001316571 Acris crepitans Species 0.000 description 1
- 241000269331 Ambystoma Species 0.000 description 1
- 241000269332 Ambystoma mexicanum Species 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000943303 Enterococcus faecalis ATCC 29212 Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000327262 Eurycea cirrigera Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 241000269472 Litoria Species 0.000 description 1
- 241001669571 Litoria chloris Species 0.000 description 1
- 241000896354 Lucifuga Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241001375823 Plethodon dorsalis Species 0.000 description 1
- 241001288004 Plethodon ventralis Species 0.000 description 1
- 241001142129 Pseudacris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241001301992 Rana clamitans Species 0.000 description 1
- 241001124583 Rhacophorus Species 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000269622 Salamandridae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- -1 dimethoxy penicillin Chemical compound 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/245—Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/265—Enterobacter (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/38—Assays involving biological materials from specific organisms or of a specific nature from fungi from Aspergillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
- G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/4606—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates from amphibians
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
Abstract
Description
家族 | 物种 | 生物体 | 栖居类型 |
无肺螈科 | Desmognathusfolkertsi | 蝾螈 | 溪流边缘 |
无肺螈科 | Desmognathusfuscus | 蝾螈 | 溪流边缘 |
无肺螈科 | Desmognathusquadramaculatus | 蝾螈 | 溪流边缘 |
无肺螈科 | Eurycea cirrigera | 蝾螈 | 沼泽 |
无肺螈科 | Euryceaguttolineata | 蝾螈 | 溪流边缘 |
无肺螈科 | Eurycea lucifuga | 蝾螈 | 穴居 |
无肺螈科 | Plethodon aureolus | 蝾螈 | 疏林森林 |
无肺螈科 | Plethodonchattahoochee | 蝾螈 | 疏林森林 |
无肺螈科 | Plethodonchlorobryonis | 蝾螈 | 疏林森林 |
无肺螈科 | Plethodon dorsalis | 蝾螈 | 疏林森林 |
无肺螈科 | Plethodonocmulgee | 蝾螈 | 疏林森林 |
无肺螈科 | Plethodonoconaluftee | 蝾螈 | 疏林森林 |
美西螈 | Ambystomaopacum | 蝾螈 | 沼泽 |
Ranidae | Rana clamitans | 蛙 | 沼泽 |
Hylidae | Acris crepitans | 蛙 | 溪流边缘 |
Hylidae | Pseudacris crucifer | 蛙 | 溪流边缘 |
革兰氏阴性杆菌分离物数 | 革兰氏阳性杆菌分离物数 | 革兰氏阴性球菌分离物数 | 革兰氏阳性球菌分离物数 | |
蝾螈细菌分离物 | 306 | 20 | 25 | 5 |
蛙细菌分离物 | 37 | 10 | 7 | 7 |
分离号 | 菌落形式 | 边缘形式 | 隆起形式 | 颜色 | 外表 | 革兰氏反应 | 源生物体 |
DQ001D | 环形 | 完整 | 中央凸 | 不透明的白色边缘,白色中心 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
PO014 | 环形 | 完整 | 凸起 | 桃红色中心,白色边缘 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
PO019 | 环形 | 完整 | 凸起 | 黄色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
PO026 | 环形 | 完整 | 凸起 | 不透明白色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
PO027 | 环形 | 波浪形 | 凸起 | 白色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
AC021 | 环形 | 波浪形 | 凸起 | 不透明白色 | 光滑 | 革兰氏阴性杆菌 | 蛙 |
AC024 | 不规则形 | 波浪形 | 凸起 | 白色 | 光滑 | 革兰氏阴性杆菌 | 蛙 |
PC017 | 环形 | 完整 | 凸起 | 白色 | 光滑 | 革兰氏阴性杆菌 | 蛙 |
PD026 | 环形 | 完整 | 凸起 | 不透明桃红色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
EG006 | 不规则形 | 叶状 | 凸起 | 桔黄色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
EC009 | 点状 | 完整 | 凸起 | 黄色 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
EC024 | 不规则形 | 叶状 | 中央凸起 | 不透明白色边缘,白色中心 | 光滑 | 革兰氏阴性杆菌 | 蝾螈 |
RC003 | 环形 | 锯齿状 | 凸起 | 紫色 | 光滑 | 革兰氏阳性球菌 | 蛙 |
抑制带(mm) | ||||
分离物 | Enterococcusfaecalis | 大肠杆菌 | Staphylococcusaureus | Pseudomonasaeruginosa |
DQ001D | 37.0 | |||
PO014 | 17.5 | >50 | ||
PO019 | 45.0 | |||
PO026 | 25.0 | |||
PO027 | 23.0 | 22.0 | ||
AC021 | 27.0 | 30.5 | ||
AC024 | 29.5 | 32.0 | ||
PC017 | 22.0 | |||
PD026 | >50 | |||
EG006 | >50 | >50 | ||
EC024 | 35.5 | 32.0 | ||
EC009 | >50 | >50 | ||
RC003 | 44.0 | 45.5 |
Claims (19)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26002201P | 2001-01-05 | 2001-01-05 | |
US60/260,022 | 2001-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1455673A true CN1455673A (zh) | 2003-11-12 |
Family
ID=22987486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN02800047A Pending CN1455673A (zh) | 2001-01-05 | 2002-01-04 | 分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1357921A2 (zh) |
JP (1) | JP2004521935A (zh) |
CN (1) | CN1455673A (zh) |
AU (1) | AU2002246943A1 (zh) |
BR (1) | BR0203466A (zh) |
CA (1) | CA2433910A1 (zh) |
WO (1) | WO2002078720A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100522993C (zh) * | 2006-05-30 | 2009-08-05 | 中国科学院昆明动物研究所 | 无指盘臭蛙抗菌肽 |
CN112800543A (zh) * | 2021-01-27 | 2021-05-14 | 中国空气动力研究与发展中心计算空气动力研究所 | 一种基于改进Goman模型的非线性非定常气动力建模方法 |
CN115044521A (zh) * | 2021-03-09 | 2022-09-13 | 大象株式会社 | L-赖氨酸生产能力得到提高的谷氨酸棒状杆菌突变株及利用其的l-赖氨酸的生产方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105246495B (zh) | 2013-01-09 | 2021-08-10 | Ise专业检测与咨询服务有限公司 | 来自非哺乳动物组织的脱细胞化的生物材料 |
FR3038983A1 (fr) * | 2015-07-13 | 2017-01-20 | Centre Nat De La Rech Scient (Cnrs) | Composes inhibiteurs de pseudomonas aeruginosa |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
SE9604593D0 (sv) * | 1996-12-13 | 1996-12-13 | Sbl Vaccin Ab | Antimicrobially active polypeptides |
-
2002
- 2002-01-04 JP JP2002576985A patent/JP2004521935A/ja active Pending
- 2002-01-04 CN CN02800047A patent/CN1455673A/zh active Pending
- 2002-01-04 BR BR0203466-2A patent/BR0203466A/pt not_active IP Right Cessation
- 2002-01-04 CA CA002433910A patent/CA2433910A1/en not_active Abandoned
- 2002-01-04 AU AU2002246943A patent/AU2002246943A1/en not_active Abandoned
- 2002-01-04 WO PCT/US2002/000217 patent/WO2002078720A2/en active Application Filing
- 2002-01-04 EP EP02714692A patent/EP1357921A2/en not_active Withdrawn
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100522993C (zh) * | 2006-05-30 | 2009-08-05 | 中国科学院昆明动物研究所 | 无指盘臭蛙抗菌肽 |
CN112800543A (zh) * | 2021-01-27 | 2021-05-14 | 中国空气动力研究与发展中心计算空气动力研究所 | 一种基于改进Goman模型的非线性非定常气动力建模方法 |
CN112800543B (zh) * | 2021-01-27 | 2022-09-13 | 中国空气动力研究与发展中心计算空气动力研究所 | 一种基于改进Goman模型的非线性非定常气动力建模方法 |
CN115044521A (zh) * | 2021-03-09 | 2022-09-13 | 大象株式会社 | L-赖氨酸生产能力得到提高的谷氨酸棒状杆菌突变株及利用其的l-赖氨酸的生产方法 |
CN115044521B (zh) * | 2021-03-09 | 2023-11-03 | 大象株式会社 | L-赖氨酸生产能力得到提高的谷氨酸棒状杆菌突变株及利用其的l-赖氨酸的生产方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2004521935A (ja) | 2004-07-22 |
WO2002078720A3 (en) | 2002-12-05 |
BR0203466A (pt) | 2003-03-11 |
AU2002246943A1 (en) | 2002-10-15 |
CA2433910A1 (en) | 2002-10-10 |
EP1357921A2 (en) | 2003-11-05 |
WO2002078720A2 (en) | 2002-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bizuye et al. | Isolation and screening of antibiotic producing actinomycetes from soils in Gondar town, North West Ethiopia | |
Nantz et al. | Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention | |
Adeyemi | Isolation and screening of endophytic fungi from three plants used in traditional medicine in Nigeria for antimicrobial activity | |
Bankole et al. | Synergistic antimicrobial activities of phytoestrogens in crude extracts of two sesame species against some common pathogenic microorganisms | |
Lovy et al. | Activity of edible mushrooms against the growth of human T4 leukemic cancer cells, HeLa cervical cancer cells, and Plasmodium falciparum | |
Dildora et al. | APPLICATION AREAS OF BIOLOGICALLY ACTIVE METABOLITES PRODUCED BY ENDOPHITE BACTERIA | |
Akintola et al. | Anti-tuberculosis activities of the crude methanolic extract and purified fractions of the bulb of Crinum jagus | |
Khan et al. | Study of antidiabetic activities of endophytic fungi isolated from plants | |
Sangdee et al. | Effects of mycelial extract and crude protein of the medicinal mushroom, Ophiocordyceps sobolifera, on the pathogenic fungus, Candida albicans | |
Ilyas et al. | An assemblages of fungal endophytes isolated from medicinal plants collected from Toba and Samosir, North Sumatra | |
CN1455673A (zh) | 分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物 | |
CN106479904A (zh) | 一株平沙绿僵菌及其应用 | |
CN104736692B (zh) | 深棕色宛氏拟青霉gpp1101b菌株及利用其的制剂 | |
US20030072829A1 (en) | Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom | |
Caesario et al. | Hematological Profile of Mice After Ethyl Acetate Extract of Fungus Comb of Indo-Malayan Termite (Macrotermes gilvus Hagen) Mound Supplementation in Regulating Lipopolysaccharide-induced Inflammatory Response. | |
Hassan et al. | Correlation between aspergillosis and renal function profile analysis in broilers of Diyala province–Iraq | |
Fayad et al. | A systematic multicellular spheroids screening approach lead to the identification of antineoplastic activity in three different plant extracts from the Egyptian flora | |
El-Salam et al. | Histopathological changes in diseased and treated catfish (Clarias gariepinus) by ciprofloxacin and clove oil | |
Hinterdobler et al. | Chemical diversity and richness of fungal endophytes from Costa Rican Palicourea and Psychotria species (Rubiaceae) | |
Ellis et al. | Cryptococcosis and the ecology of Cryptococcus neoformans | |
Bara et al. | Anti-UV, SPF, and Antibacterial Activities of Gorgonian Mopsella cf. aurantia. | |
Lertcanawanichakul et al. | In-vitro Anti-food poisoning bacteria and cytotoxic activities of bioactive compounds produced by Streptomyces sp. A10 isolated from fermented food | |
NOURI | The Inhibitory Efficiency of Flavonoid Extract of Black Mustard Seeds (Brassica nigra) and cold aqueous extract of Euphorbia prostrata L. on growth of Staphylococcus aureusinvitro and invivo | |
Mbilu | Antimicrobial Activity of Endophytic Fungi Isolated from Warburgia Ugandensis against Candida albicans | |
Radhika et al. | Study on Immunostimulatory property of few Seaweeds injected intraperitoneally |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: PULENTUN RESEARCH CO.,LTD. Free format text: FORMER OWNER: KAIMIN INDUSTRY CO., LTD. Free format text: FORMER OWNER: PULENTUN RESEARCH CO.,LTD. Effective date: 20050121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050121 Address after: Georgia, USA Applicant after: Preeton Research Co. Address before: Iowa, USA Applicant before: KEMIN INDUSTRIES, Inc. Co-applicant before: Preeton Research Co. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |